Health Care's Sweet 16 Stocks: Novartis vs. Bristol-Myers Squibb

Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted the brackets of would-be prognosticators.

Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner take-all tournament determined by the collective intelligence of our CAPS community.

This matchup will feature a heavyweight bout between Novartis and Bristol-Myers Squibb. Watch and find out which stock gets eliminated and which will advance to the next round.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know whether J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 30, 2013, at 5:20 PM, cdb5556 wrote:

    not too crazy about either of these dinosaurs. Plavix patent expiration kills BMS, and Novartis is or has soon lost patent protection on Diovan. Novartis may have the better pipeline. I never pay attention to the pipeline drugs till they actually have a name..most of the numbered compounds end up never reaching the pharmacy.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2338260, ~/Articles/ArticleHandler.aspx, 12/20/2014 8:13:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement